Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LAT1 CRISPR Activation Plasmid (h): sc-401609-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LAT1 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- LAT1 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by LAT1 CRISPR Activation Plasmid (h) and LAT1 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the SLC7A5 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LAT1 Antibody (D-10): sc-374232
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LAT1 CRISPR Activation Plasmid (h) | sc-401609-ACT | 20 µg | $397.00 |
SLC7A5 encodes the human L-type amino acid transporter 1 (LAT1), a high-affinity transporter that mediates uptake of large neutral amino acids such as leucine in conjunction with the heavy chain SLC3A2 (CD98). By controlling intracellular amino acid availability, LAT1 supports nutrient sensing and anabolic metabolism, influencing signaling networks such as mTORC1 and integrated stress response pathways that couple transport to growth and proteostasis. LAT1 activity is frequently studied in contexts of metabolic reprogramming, barrier transport biology, and proliferative phenotypes where amino acid flux constrains biosynthetic capacity. Dysregulated SLC7A5 expression has been associated with altered nutrient dependency and transporter-linked vulnerabilities across multiple disease models, making it a widely used entry point for interrogating amino acid–driven signaling.
LAT1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous SLC7A5 expression without altering the underlying DNA sequence.
LAT1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the SLC7A5 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the SLC7A5 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous LAT1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native SLC7A5 locus and enabling the study of LAT1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of LAT1 pathway restoration in tumor cells with silenced or reduced SLC7A5 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.